MONTRÉAL, April 8, 2021 /CNW/ - Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., today announced the launch and availability of a new autoinjector for AJOVY® (fremanezumab). AJOVY® is a subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month. When launched in 2020, AJOVY® was available in a prefilled syringe only. The product is now available in two latex-free1 formats: a new autoinjector and a prefilled syringe.
Read MoreMONTREAL, April 8, 2021 /CNW Telbec/ - Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing first-in-class pro-resolving drug LAU-7b, today announces that the independent Data Safety Monitoring Board (DSMB) for the Phase 2 RESOLUTION study in hospitalized patients with COVID-19 unanimously recommended to continue the study without modification following a pre-scheduled safety review and mid-study interim futility analysis of unblinded efficacy data from the first 102 patients treated in the study. The company also reports the completion of enrollment in its Phase 2 APPLAUD study in adult patients with Cystic Fibrosis (CF).
Read MoreEli Lilly and Company and Incyte shared additional data that showed baricitinib in combination with remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with remdesivir.
Read MoreThe BIOQuébec network consists of over 100 members of the life sciences industry. Discover more about Endoceutics by viewing its profile!
Read MoreThe Institut national d’excellence en santé et services sociaux (INESSS) recommended to use an affordable genetic screening test to avoid cases where patients experience complications following the Xeloda chemotherapy treatment, commonly known as 5-FU in its intravenously administered form.
Read More